MX2009006966A - Tratamientos para cancer a base de romidepsina. - Google Patents

Tratamientos para cancer a base de romidepsina.

Info

Publication number
MX2009006966A
MX2009006966A MX2009006966A MX2009006966A MX2009006966A MX 2009006966 A MX2009006966 A MX 2009006966A MX 2009006966 A MX2009006966 A MX 2009006966A MX 2009006966 A MX2009006966 A MX 2009006966A MX 2009006966 A MX2009006966 A MX 2009006966A
Authority
MX
Mexico
Prior art keywords
romidepsin
adducts
oligomerized
dimerized
cancer
Prior art date
Application number
MX2009006966A
Other languages
English (en)
Inventor
Gregory L Verdine
Nicholas H Vrolijk
Original Assignee
Gloucester Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gloucester Pharmaceuticals Inc filed Critical Gloucester Pharmaceuticals Inc
Publication of MX2009006966A publication Critical patent/MX2009006966A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/15203—Properties of the article, e.g. stiffness or absorbency
    • A61F13/15252—Properties of the article, e.g. stiffness or absorbency compostable or biodegradable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/49—Absorbent articles specially adapted to be worn around the waist, e.g. diapers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/505—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators with separable parts, e.g. combination of disposable and reusable parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un proceso mejorado para preparar romidepsina. El proceso incluye producir, purificar o almacenar romidepsina bajo condiciones que impidan la formación de aductos no deseados. Se ha descubierto que purificar romidepsina a un pH aparente inferior a aproximadamente 6.0 (por ejemplo, un pH aparente entre 4.0 y 6.0) impide la reducción del enlace de disulfuro de romidepsina y la formación subsecuente de aductos dimerizados, oligomerizados o polimerizados. La invención proporciona también composiciones de romidepsina monomérica libre de aductos dimerizados, oligomerizados o polimerizados.
MX2009006966A 2006-12-29 2007-12-28 Tratamientos para cancer a base de romidepsina. MX2009006966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88271206P 2006-12-29 2006-12-29
PCT/US2007/089070 WO2008083290A1 (en) 2006-12-29 2007-12-28 Romidepsin-based treatments for cancer

Publications (1)

Publication Number Publication Date
MX2009006966A true MX2009006966A (es) 2009-12-09

Family

ID=39588997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006966A MX2009006966A (es) 2006-12-29 2007-12-28 Tratamientos para cancer a base de romidepsina.

Country Status (9)

Country Link
US (2) US20100093610A1 (es)
EP (4) EP2124990A4 (es)
JP (2) JP2010514802A (es)
CN (2) CN101687010A (es)
AU (1) AU2007342030B2 (es)
BR (1) BRPI0720734A2 (es)
CA (1) CA2674313A1 (es)
MX (1) MX2009006966A (es)
WO (1) WO2008083290A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
CN101801994A (zh) 2006-12-29 2010-08-11 格洛斯特制药公司 制备Romidepsin
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US8859502B2 (en) * 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
PT2688572T (pt) * 2011-03-21 2017-06-02 Valcuria Ab Composição farmacêutica com um inibidor de hdac e um esteroide e sua utilização
MX2014008390A (es) * 2012-01-12 2014-09-22 Celgene Corp Formulaciones de romidepsina y sus usos.
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN103110931B (zh) * 2013-03-19 2015-08-19 广州迈达康医药科技有限公司 制备罗咪酯肽脂质体的方法
CN104447950A (zh) * 2013-09-18 2015-03-25 上海医药工业研究院 一种罗米地辛的分离纯化方法
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
EP3902908A4 (en) * 2018-12-24 2024-01-03 Pro Farm Group, Inc. METHOD FOR INCREASING PRODUCTION OF ROMIDEPSIN FROM A FERMENTATION BROTH

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US5837458A (en) * 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6828302B1 (en) * 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
BR0016154A (pt) * 1999-12-08 2003-02-25 Xcyte Therapies Inc Depsipeptida e seus congêneres papa uso como imunossupressores
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
DE60137932D1 (de) * 2000-07-17 2009-04-23 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
WO2002020817A1 (en) * 2000-09-01 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2457043A1 (en) * 2001-08-21 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20030134423A1 (en) * 2002-01-04 2003-07-17 Chu Yong Liang Compounds for delivering substances into cells
WO2003070754A1 (fr) * 2002-02-20 2003-08-28 Minoru Yoshida Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
CA2632078C (en) * 2002-03-04 2012-08-14 Sloan-Kettering Institute For Cancer Research Methods of inducing terminal differentiation
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
EP1492596A1 (en) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
ES2342378T3 (es) * 2002-08-20 2010-07-06 Astellas Pharma Inc. Inhibidor de degradacion de matriz extracelular del cartilago artrodial.
AU2003261801A1 (en) * 2002-08-30 2004-03-19 Yamanouchi Pharmaceutical Co., Ltd. Novel depsipeptide compound
AU2003259521A1 (en) * 2002-09-13 2004-04-30 Mcguire Va Medical Center 111K Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
SE0300098D0 (sv) * 2003-01-15 2003-01-15 Forskarpatent I Syd Ab Use of cyclin D1 inhibitors
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
JPWO2004074478A1 (ja) * 2003-02-19 2006-06-01 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
WO2004096289A1 (ja) * 2003-04-25 2004-11-11 Fujisawa Pharmaceutical Co 遺伝子導入効率増強剤
PL2238982T3 (pl) * 2003-06-27 2013-03-29 Astellas Pharma Inc Środek do terapii mięsaka tkanek miękkich
AR047938A1 (es) 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
EP1689445B1 (de) * 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
WO2005058298A2 (en) 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US20060228404A1 (en) * 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
WO2005123089A2 (en) * 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US7284176B2 (en) * 2004-07-15 2007-10-16 Nec Laboratories America, Inc. Externally-loaded weighted random test pattern compression
US20060018921A1 (en) * 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
CA2586228A1 (en) * 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
CA2610854A1 (en) * 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
US7943568B2 (en) * 2005-09-30 2011-05-17 The Ohio State University Research Foundation Antitumor agents
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
CN101801994A (zh) * 2006-12-29 2010-08-11 格洛斯特制药公司 制备Romidepsin
WO2008088331A1 (en) * 2007-01-19 2008-07-24 Gloucester Pharmaceuticals Methods for increasing levels of human fetal hemoglobin
EP2117556A2 (en) * 2007-01-23 2009-11-18 Gloucester Pharmaceuticals, Inc. Combination therapy comprising romidepsin and i.a. bortezomib
MX2011001132A (es) * 2008-07-30 2011-08-17 Gloucester Pharmaceuticals Inc Tratamiento acelerado.
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy
CA2804795A1 (en) * 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US8859502B2 (en) * 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia

Also Published As

Publication number Publication date
US20100093610A1 (en) 2010-04-15
EP2556838A1 (en) 2013-02-13
JP2013240332A (ja) 2013-12-05
CA2674313A1 (en) 2008-07-10
EP2450049A1 (en) 2012-05-09
JP2010514802A (ja) 2010-05-06
CN103497238A (zh) 2014-01-08
EP2124990A1 (en) 2009-12-02
AU2007342030A1 (en) 2008-07-10
BRPI0720734A2 (pt) 2014-01-07
EP2124990A4 (en) 2010-04-21
AU2007342030B2 (en) 2013-08-15
JP5775114B2 (ja) 2015-09-09
CN101687010A (zh) 2010-03-31
EP2815761A1 (en) 2014-12-24
WO2008083290A1 (en) 2008-07-10
US20130236928A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
MX2009006966A (es) Tratamientos para cancer a base de romidepsina.
MX2009006969A (es) Purificacion de romidepsina.
MX2020002183A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.
IL258880A (en) Compounds of diarylhydantoin
WO2006037024A3 (en) Salts of decitabine
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
WO2006034154A3 (en) Salts of 5-azacytidine
SG144925A1 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
MX2009006891A (es) Anticuerpos cd44.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
TN2009000194A1 (en) Novel antiproliferation antibodies
MX2021012769A (es) Anticuerpos bloqueadores cd73.
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
TW200744577A (en) Method for treating osteoarthritis
MXPA05007339A (es) Derivados de alfa-aminoamida utiles como agentes antimigranosos.
WO2006131512A3 (en) Anti-thrombotic agents

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CELGENE CORPORATION.*

FA Abandonment or withdrawal